Urol. praxi. 2021;22(4):177-180 | DOI: 10.36290/uro.2021.016

Diagnosis and staging of renal cell carcinoma

MUDr. Veronika Lounová, MUDr. Vladimír Študent, Ph.D.
Urologická klinika FN a LF UP Olomouc

Renal cell carcinoma represents 2-3 % of all cancers. Incidence in the Czech Republic is the highest in the world and is still increasing. Most of the tumors are detected incidentally thanks to imaging methods. Tumors are usually found in an early stage when the surgical treatment is curable. The purpose of this article is to present the current view on the diagnosis and staging of renal cell carcinoma.

Keywords: renal cell carcinoma, diagnosis, staging, imaging methods.

Received: March 27, 2021; Revised: April 17, 2021; Accepted: April 20, 2021; Prepublished online: April 20, 2021; Published: November 24, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lounová V, Študent V. Diagnosis and staging of renal cell carcinoma. Urol. praxi. 2021;22(4):177-180. doi: 10.36290/uro.2021.016.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of Renal Cell Carcinoma. Eur Urol 2019; 75(1): 74-84. Go to original source... Go to PubMed...
    2. Incidence a mortalita karcinomu ledviny [online]. Databáze UZIS [cit. 2021-03-22] Dostupné z: https://www.svod.cz/analyse.php?modul=incmor#.
    3. Bergström A, Hsieh CC, Lindblad P, et al. Obesity and renal cell cancer--a quantitative review. Br J Cancer. 2001; 85(7): 984-990. Go to original source... Go to PubMed...
    4. Clague J, Lin J, Cassidy A, et al. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev 2009; 18(3): 801-807. Go to original source... Go to PubMed...
    5. Kováčová-Majerová Z, Zachoval R, Andriychuk Y. Karcinom ledviny s Xp 11.2 translokací. Urol. praxi 2014; 15(4): 182-184.
    6. Ball MW, Shuch BM. Inherited kidney cancer syndromes. Curr Opin Urol 2019; 29(4): 334-343. Go to original source... Go to PubMed...
    7. Ljunberg B, Albiges L, Bedke J, et al. Renal cell carcinoma, EAU Guidelines 2020: 12-22.
    8. Burešová E, Čtvrtlík F, Študent V. Diagnostika a chirurgická léčba karcinomu ledviny s nádorovým trombem. Urol. praxi 2010; 11(3): 149-151.
    9. Kim HL, Belldegrun AS, Freitas DG, et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 2003; 170(5): 1742-1746. Go to original source... Go to PubMed...
    10. Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev Urol 2002; 4(4): 163-170. Go to PubMed...
    11. Israel GM, Bosniak MA. Pitfalls in renal mass evaluation and how to avoid them. Radiographics 2008; 28(5): 1325-1338. Go to original source... Go to PubMed...
    12. Janus CL, Mendelson DS. Comparison of MRI and CT for study of renal and perirenal masses. Crit Rev Diagn Imaging 1991; 32(2): 69-118.
    13. Krestin GP, Gross-Fengels W, Marincek B. Bedeutung der Magnetresonanztomographie (MRT) für die Diagnostik und Stadieneinteilung des Nierenzellkarzinoms [The importance of magnetic resonance tomography in the diagnosis and staging of renal cell carcinoma]. Radiologe 1992; 32(3): 121-6. German. Go to PubMed...
    14. Kabala JE, Gillatt DA, Persad RA, et al. Magnetic resonance imaging in the staging of renal cell carcinoma. Br J Radiol 1991; 64(764): 683-689. Go to original source... Go to PubMed...
    15. Defortescu G, Cornu JN, Béjar S, et al. Diagnostic performance of contrast-enhanced ultrasonography and magnetic resonance imaging for the assessment of complex renal cysts: a prospective study. Int J Urol. 2017; 24(3): 184-189. Go to original source... Go to PubMed...
    16. Park JW, Jo MK, Lee HM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int 2009; 103(5): 615-619. Go to original source... Go to PubMed...
    17. Rioja J, de la Rosette JJ, Wijkstra H, Laguna MP. Advances in diagnosis and follow-up in kidney cancer. Curr Opin Urol 2008; 18(5): 447-54. Go to original source... Go to PubMed...
    18. Graser A, Zech CJ, Stief CG, Reiser MF, Staehler M. Bildgebung des Nierenzellkarzinoms [Imaging renal cell carcinoma]. Urologe A. 2009; 48(4): 427-36; quiz 437-8. German. Go to original source... Go to PubMed...
    19. Marconi L, Dabestani S, Lam TB, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol 2016; 69(4): 660-673. Go to original source... Go to PubMed...
    20. Keegan KA, Schupp CW, Chamie K, et al. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol 2012; 188(2): 391-397. Go to original source... Go to PubMed...
    21. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168(6): 2395-400. Go to original source... Go to PubMed...
    22. Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007; 25(11): 1316-22. Go to original source... Go to PubMed...
    23. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19(6): 1649-1657. Go to original source... Go to PubMed...
    24. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 97(7): 1663-1671. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.